Legence Corp. Class A LGN 深 滬
已收盤 02-06 16:00:00 美东时间
48.87
+4.440
+9.99%
華盛通- 最 高48.95
- 今 開44.71
- 成交量 105.30万股
- 最 低 44.71
- 昨 收 44.43
- 總市值 52.73亿
- 52周最高 52.7351
- 市盈率 靜 560.44
- 換手率 0.98%
- 52周最低 26.96
- 委 比 55.47%
- 總股本 1.08亿
- 歷史最高 52.7351
- 量 比 0.83
- 振 幅 9.54%
- 歷史最低 26.96
- 每 手 1
- 風險率 6.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价
今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元
01-29 11:06
美股大行评级 | 斯伦贝谢、SouthState Bank、西屋制动、特里科银行获多家大行上调目标价；苹果、meta、微软等绩前遭下调目标价
今日重点评级关注：Oppenheimer：维持Pelthos Therapeutics"跑赢大市"评级，目标价从57美元升至60美元；Small Cap Consumer Research：维持Lands' End"买入"评级，目标价从20美元升至45美元
01-27 10:02
美股大行评级 | 潜在涨幅258.31%！Tempest Therapeutics获HC Wainwright上调评级至"买入"，目标价11美元
今日重点评级关注：HC Wainwright & Co.：上调Tempest Therapeutics评级至"买入"，目标价11美元；Guggenheim：维持Sportradar Gr"买入"评级，目标价从34美元升至35美元
01-23 19:46
Tigress Financial Maintains Buy on Legence, Raises Price Target to $60
Tigress Financial analyst Ivan Feinseth maintains Legence (NASDAQ:LGN) with a Buy and raises the price target from $54 to $60.
01-22 23:55
Legence Announces Full Exercise and Closing of Over-allotment Option
<p>Legence Corp announced that underwriters of a secondary public offering of 8,402,178 shares of its Class A common stock have exercised their option to purchase an additional 1,260,326 shares at $45.00 per share. The company did not sell any shares or receive proceeds from the sale. Goldman Sachs and Jefferies served as joint lead book-running managers, with participation from other prominent financial institutions. The offering was conducted u...
01-08 21:00
Legence Completes Acquisition of Bowers
Legence Corp. has completed its acquisition of The Bowers Group, a premier mechanical contractor, for $325 million in cash and stock, with an additional $50 million deferred payment. The acquisition is expected to enhance Legence's service offerings and strengthen its position in the mechanical, plumbing, and process system solutions market. Legence CEO Jeff Sprau expressed excitement about the strategic move and the potential for greater success...
01-02 21:55
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
Stifel Maintains Buy on Legence, Raises Price Target to $50
Stifel analyst Brian Brophy maintains Legence (NASDAQ:LGN) with a Buy and raises the price target from $47 to $50.
2025-12-17 01:20
Legence shares are trading lower after the company announced a secondary offering of 7 million Class A shares.
Legence shares are trading lower after the company announced a secondary offeri...
2025-12-10 05:21
Legence Announces Secondary Underwritten Public Offering of Class A Common Stock
Legence Corp. announced that Blackstone Inc.-affiliated selling stockholders plan to offer 7 million shares of Legence's Class A common stock in a secondary public offering, with an option for underwriters to purchase up to an additional 1.05 million shares. Legence is not selling shares and will not receive proceeds, though it will incur related costs. Goldman Sachs and Jefferies are joint lead managers, with Blackstone Capital Markets as co-man...
2025-12-09 21:11
